If you loved our Explainer on Genomics, you'll love this new summarised version. This short report takes you through the key BIA member companies working in the AMR space, and explains the cutting-edge work taking place in the UK.
As we settle into the rhythms of daily life and gather our thoughts about the year ahead, our policy experts have weighed in on what the life sciences sector might expect in 2026.
OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.
Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.
Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.
Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.
This webinar spotlighted the latest capabilities from Our Future Health, the UK’s largest health research programme, now offering imputed and geographic data, dispensed medication records, and direct participant recruitment pathways.
